# Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

> **NCT03245008** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 626 (actual)

## Conditions studied

- Osteoarthritis, Knee / Osteoarthritis, Hip

## Interventions

- **DRUG:** MT-5547
- **DRUG:** MT-5547-matching placebo

## Key facts

- **NCT ID:** NCT03245008
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-08
- **Primary completion:** 2019-12-14
- **Final completion:** 2021-03-09
- **Target enrollment:** 626 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245008, "Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03245008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*